8-K current report · filed Nov 5, 2026

Nkarta, Inc. (NKTX) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1NKTX overview

Short answer

Nkarta, Inc. (NKTX) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for the quarter ended September 30, 2026.

Nkarta, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results announced for the quarter ended September 30, 2026
  • Full operating and financial details available in Exhibit 99.1, the company’s earnings press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 2026 net loss $33.3M, or $0.45 per share, versus $21.7M, or $0.29, in Q3 2025
  • R&D spending rose to $29.5M from $20.2M, reflecting accelerated NKX019 clinical development
  • Cash, restricted cash and investments totaled $216.0M, with management projecting funding into 2029
  • Initial NKX019 clinical data in myositis and systemic sclerosis scheduled for ACR Convergence 2026
  • Ntrust dosing uses 4 billion cells per dose across 3 doses, totaling 12 billion cells per patient cycle

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Nkarta, Inc. 8-K filings

Get the next NKTX 8-K as it lands

Follow NKTX for push alerts, or ask the research agent what this filing means.